SCHEMBL2384768

SCHEMBL2384768

Cc1ccc(-c2nccc(N3CCN(C)CC3)n2)cc1F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 7/20 0.60
ALDH1A1 P00352 6/20 0.60
CYP3A4 P08684 5/20 0.60
HSD17B10 Q99714 4/20 0.60
USP2 O75604 3/20 0.60
CLK4 Q9HAZ1 2/20 0.60
CASP1 P29466 1/20 0.60
CASP7 P55210 1/20 0.60
CYP2D6 P10635 4/20 0.57
ALOX15 P16050 1/20 0.57
TSHR P16473 2/20 0.56
CYP2C19 P33261 3/20 0.53
KDM4E B2RXH2 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
TDP1 Q9NUW8 1/20 0.50
HRH4 Q9H3N8 7/20 0.49
HRH3 Q9Y5N1 2/20 0.49
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2384465 0.84 CYP1A2 (0.58) CYP1A2ALDH1A1CYP3A4HSD17B10USP2
SCHEMBL2386722 0.83 CYP1A2 (0.64) CYP1A2ALDH1A1CYP3A4HSD17B10USP2
SCHEMBL2388259 0.83 TLR9 (0.50) KDM4EHRH4HRH3LMNATP53
SCHEMBL2386314 0.80 HRH4 (0.62) CYP1A2ALDH1A1CYP3A4USP2CLK4
SCHEMBL2381878 0.76 CYP1A2 (0.74) CYP1A2ALDH1A1CYP3A4HSD17B10USP2
SCHEMBL2383996 0.76 CYP1A2 (0.66) CYP1A2ALDH1A1CYP3A4HSD17B10USP2
SCHEMBL2386656 0.75 HRH4 (0.59) MEN1KMT2AHRH4KCNH2
SCHEMBL2384028 0.73 CYP1A2 (0.63) CYP1A2ALDH1A1CYP3A4HSD17B10USP2
SCHEMBL14029975 0.71 HRH4 (0.67) CYP1A2ALDH1A1CYP3A4HSD17B10USP2
SCHEMBL2560523 0.70 NISCH (0.49) CLK4PIK3CDDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009035671-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-19 WO claimed
US-20090069305-A1 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-12 US claimed
US-8022209-B2 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2011-09-20 US disclosed
US-8022209-B2 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2011-09-20 US disclosed
US-8022209-B2 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2011-09-20 US disclosed
WO-2009035671-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-19 WO disclosed
WO-2009035671-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-19 WO disclosed
US-20090069305-A1 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-12 US disclosed
US-20090069305-A1 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-12 US disclosed
US-20090069305-A1 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069305-A1 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor HRH4, HRH3, HRH2 CYP1A2 2697/4885ALDH1A1 3938/4885CYP3A4 735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.